CEO · Lupvindol Bioscience · company speakers →
Advancing a new therapeutic class to market requires a balance of strong science, solid IP protection, and a regulatory path that supports early access. Hunter Land (CEO) shares how Lupvindol is progressing its CBD–corticosteroid combinations for canine IBD and equine osteoarthritis through compelling efficacy data, robust patent strategy, and the FDA’s expanded conditional approval route.
Is this you? Claim this profile →
No public contact links on file.
Sourcing speakers for your event?
Browse the speaker directory →